These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25250422)

  • 21. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.
    Campochiaro PA; Hafiz G; Channa R; Shah SM; Nguyen QD; Ying H; Do DV; Zimmer-Galler I; Solomon SD; Sung JU; Syed B
    Ophthalmology; 2010 Dec; 117(12):2387-2394.e1-5. PubMed ID: 20630595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.
    Jonas JB; Libondi T; Schlichtenbrede F; Schmidbauer M
    Acta Ophthalmol; 2010 Mar; 88(2):e24-5. PubMed ID: 19493250
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up.
    Pece A; Isola V; Piermarocchi S; Calori G
    Br J Ophthalmol; 2011 Jan; 95(1):56-68. PubMed ID: 20601660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment.
    DeCroos FC; Ehlers JP; Stinnett S; Fekrat S
    Curr Eye Res; 2011 Dec; 36(12):1164-70. PubMed ID: 21978179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
    Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for perifoveal telangiectasia.
    Jonas JB; Libondi T; von Baltz S; Beutelspacher S
    Acta Ophthalmol; 2011 Nov; 89(7):e607-8. PubMed ID: 20946328
    [No Abstract]   [Full Text] [Related]  

  • 29. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
    Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
    Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
    Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of retinal nonperfusion in branch retinal vein occlusion using wide-field optical coherence tomography angiography.
    Shiraki A; Sakimoto S; Tsuboi K; Wakabayashi T; Hara C; Fukushima Y; Sayanagi K; Nishida K; Sakaguchi H; Nishida K
    Acta Ophthalmol; 2019 Sep; 97(6):e913-e918. PubMed ID: 30900381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
    Niederhauser N; Valmaggia C
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice.
    Brynskov T; Kemp H; Sørensen TL
    Retina; 2014 Aug; 34(8):1637-43. PubMed ID: 24646663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.
    Ernst BJ; García-Aguirre G; Oliver SC; Olson JL; Mandava N; Quiroz-Mercado H
    Acta Ophthalmol; 2012 Nov; 90(7):e573-4. PubMed ID: 22405048
    [No Abstract]   [Full Text] [Related]  

  • 36. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion.
    Traustason S; la Cour M; Larsen M
    Br J Ophthalmol; 2014 Sep; 98(9):1208-11. PubMed ID: 24729079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Morphological characteristics of the macula in patients with retinal vein occlusion before and after the treatment: preliminary results].
    Kazarian AA; Burladinova AA; Lebenkova OA
    Vestn Oftalmol; 2014; 130(1):12-7. PubMed ID: 24684060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion.
    Sharareh B; Gallemore R; Taban M; Onishi S; Wallsh J
    Retina; 2013 Jun; 33(6):1227-31. PubMed ID: 23518900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.